Wall Street analysts expect that Global Blood Therapeutics Inc (NASDAQ:GBT) will announce earnings per share (EPS) of ($0.73) for the current quarter, according to Zacks. Zero analysts have issued estimates for Global Blood Therapeutics’ earnings. The highest EPS estimate is ($0.66) and the lowest is ($1.00). Global Blood Therapeutics posted earnings of ($0.74) per share during the same quarter last year, which would suggest a positive year over year growth rate of 1.4%. The company is expected to announce its next quarterly earnings results on Monday, March 12th.

On average, analysts expect that Global Blood Therapeutics will report full-year earnings of ($2.55) per share for the current year, with EPS estimates ranging from ($2.82) to ($2.48). For the next financial year, analysts expect that the company will post earnings of ($2.99) per share, with EPS estimates ranging from ($3.54) to ($2.38). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Global Blood Therapeutics.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings results on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.04). During the same period in the prior year, the firm earned ($0.58) EPS.

Several research firms recently commented on GBT. Oppenheimer set a $53.00 price target on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 30th. Cantor Fitzgerald set a $61.00 price target on shares of Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Monday. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Global Blood Therapeutics in a research note on Monday, October 23rd. BidaskClub downgraded shares of Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, September 14th. Finally, Zacks Investment Research raised shares of Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $36.00 price target on the stock in a research note on Tuesday, October 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $62.07.

In other news, VP Peter Radovich sold 12,500 shares of the firm’s stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $35.00, for a total value of $437,500.00. Following the sale, the vice president now directly owns 2,684 shares in the company, valued at approximately $93,940. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Charles J. Homcy sold 70,000 shares of the firm’s stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $33.97, for a total transaction of $2,377,900.00. Following the completion of the sale, the director now owns 83,328 shares in the company, valued at $2,830,652.16. The disclosure for this sale can be found here. Insiders have sold a total of 88,500 shares of company stock worth $3,003,350 in the last three months. Insiders own 5.30% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA boosted its holdings in shares of Global Blood Therapeutics by 694.9% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock valued at $124,000 after buying an additional 3,975 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of Global Blood Therapeutics by 10.1% in the 1st quarter. Legal & General Group Plc now owns 4,816 shares of the company’s stock valued at $178,000 after buying an additional 440 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Global Blood Therapeutics in the 3rd quarter valued at about $200,000. Trexquant Investment LP bought a new stake in shares of Global Blood Therapeutics in the 3rd quarter valued at about $202,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Global Blood Therapeutics in the 3rd quarter valued at about $205,000. Institutional investors and hedge funds own 90.48% of the company’s stock.

Global Blood Therapeutics (NASDAQ:GBT) traded down $3.15 during mid-day trading on Tuesday, reaching $36.25. 3,960,441 shares of the company traded hands, compared to its average volume of 1,041,337. Global Blood Therapeutics has a 52 week low of $13.35 and a 52 week high of $45.85.

TRADEMARK VIOLATION WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/15/zacks-brokerages-expect-global-blood-therapeutics-inc-gbt-will-announce-earnings-of-0-73-per-share.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Get a free copy of the Zacks research report on Global Blood Therapeutics (GBT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related stocks with our FREE daily email newsletter.